Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trialResearch in context

• Main Authors: Yong Huo (Author), Beijian Chen (Author), Qiufang Lian (Author), Shuqing Wang (Author), Lu Liu (Author), Di Lu (Author), Yanling Qu (Author), Guanzhong Zheng (Author), Lipeng Li (Author), Yuan Ji (Author), Guotian Yin (Author), Wenjun Huang (Author), Ying Xie (Author), Xinchun Yang (Author), Xiufang Gao (Author), Pei An (Author), Fengtai Xue (Author), Haoyu Li (Author), Huan Deng (Author), Li Li (Author), Lijuan Pei (Author), Lei Qian (Author)
• Format: Book
• Published: Elsevier, 2023-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary: Background: Tafolecimab, a fully human proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody developed for the treatment of hypercholesterolemia, demonstrated robust lipid-lowering efficacy and favorable safety in previous short-term studies. We aimed to assess the long-...